drugset / Trial / NCT06887985
JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)
NaSingle-groupOpen-labelTreatment
Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with Refractory Autoimmune Diseases (ADs). It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of Refractory Autoimmune Diseases (ADs).
Timeline
- Start
- 2025-03-31
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JY231 | Cell therapy | — | Intravenous |